Shortage reports
Actual shortage:
257 (7%)
Anticipated shortage:
3 (0%)
Avoided shortage:
11 (0%)
Resolved:
3300 (92%)
3571
Discontinuation Reports
To be discontinued:
24 (7%)
Discontinued:
342 (93%)
Reversed:
0 (0%)
366
143 (4%)
32 (11%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-MIRTAZAPINE | 30MG | TABLET | Resolved | 2019-03-05 | 2019-04-05 | 77893 |
| APO-MIRTAZAPINE | 45MG | TABLET | Resolved | 2024-04-26 | 2024-05-24 | 226333 |
| APO-MIRTAZAPINE | 30MG | TABLET | Resolved | 2017-03-10 | 2017-05-10 | 393 |
| APO-MIRTAZAPINE | 30MG | TABLET | Resolved | 2024-04-12 | 2024-05-24 | 225002 |
| APO-MIRTAZAPINE | 15MG | TABLET | Resolved | 2022-03-18 | 2022-06-03 | 156996 |
| APO-MIRTAZAPINE | 30MG | TABLET | Resolved | 2021-12-17 | 2022-01-06 | 151347 |
| APO-MODAFINIL | 100MG | TABLET | Resolved | 2025-03-27 | 2025-04-04 | 253502 |
| APO-MODAFINIL | 100MG | TABLET | Resolved | 2024-10-24 | 2024-12-13 | 241084 |
| APO-MODAFINIL | 100MG | TABLET | Resolved | 2022-02-04 | 2022-02-22 | 154181 |
| APO-MODAFINIL | 100MG | TABLET | Resolved | 2023-08-12 | 2023-10-27 | 201707 |
| APO-MOMETASONE | 50MCG | SPRAY, METERED DOSE | Resolved | 2022-09-01 | 2022-09-15 | 168418 |
| APO-MOMETASONE | 50MCG | SPRAY, METERED DOSE | Resolved | 2017-07-17 | 2017-08-18 | 15959 |
| APO-MOMETASONE | 50MCG | SPRAY, METERED DOSE | Resolved | 2023-06-29 | 2024-01-19 | 196946 |
| APO-MOMETASONE | 50MCG | SPRAY, METERED DOSE | Resolved | 2024-01-19 | 2024-05-22 | 216669 |
| APO-MOMETASONE | 50MCG | SPRAY, METERED DOSE | Resolved | 2019-01-30 | 2019-02-01 | 74022 |
| APO-MOMETASONE | 50MCG | SPRAY, METERED DOSE | Resolved | 2020-10-28 | 2020-11-02 | 127367 |
| APO-MONTELUKAST | 4MG | TABLET (CHEWABLE) | Resolved | 2023-09-28 | 2023-10-15 | 205495 |
| APO-MONTELUKAST | 10MG | TABLET | Resolved | 2024-09-12 | 2024-10-11 | 237363 |
| APO-MONTELUKAST | 10MG | TABLET | Resolved | 2024-02-23 | 2024-03-29 | 220456 |
| APO-MONTELUKAST | 4MG | TABLET (CHEWABLE) | Resolved | 2020-05-13 | 2020-07-06 | 114949 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-HYDROMORPHONE CR | 12MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110962 |
| APO-HYDROMORPHONE CR | 18MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110965 |
| APO-HYDROMORPHONE CR | 24MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110968 |
| APO-HYDROMORPHONE CR | 30MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110971 |
| APO-HYDROMORPHONE CR | 4.5MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110974 |
| APO-HYDROMORPHONE CR | 3MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110956 |
| APO-HYDROXYQUINE | 200MG | TABLET | Discontinued | 2018-09-07 | 2018-10-05 | 60524 |
| APO-IMIQUIMOD | Discontinued | 2019-11-26 | 2019-11-26 | 99672 | ||
| APO-IRBESARTAN | 150MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60536 |
| APO-IRBESARTAN | 300MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71237 |
| APO-IRBESARTAN | 75MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71231 |
| APO-IRBESARTAN | 300MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60539 |
| APO-IRBESARTAN | 150MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71234 |
| APO-IRBESARTAN/HCTZ | 25MG 300MG | TABLET | Discontinued | 2018-02-23 | 2018-09-15 | 40769 |
| APO-IRBESARTAN/HCTZ | 12.5MG 150MG | TABLET | Discontinued | 2018-02-23 | 2018-07-17 | 40760 |
| APO-IRBESARTAN/HCTZ | Discontinued | 2018-09-07 | 2018-09-15 | 60548 | ||
| APO-IRBESARTAN/HCTZ | 25MG 300MG | TABLET | Discontinued | 2018-02-23 | 2018-09-15 | 40766 |
| APO-IRBESARTAN/HCTZ | Discontinued | 2018-02-23 | 2018-07-17 | 40763 | ||
| APO-IRBESARTAN/HCTZ | 12.5MG 150MG | TABLET | Discontinued | 2018-02-23 | 2018-02-23 | 40757 |
| APO-LAMIVUDINE | 150MG | TABLET | Discontinued | 2018-09-07 | 2019-07-13 | 60557 |